Synth Logo

Get a high resolution logo for any domain or stock ticker — for free

Immix Biopharma Inc. (IMMX) logo

JPG 11.11 KB
Download
https://logo.synthfinance.com/ticker/IMMX
HTML
<img src="https://logo.synthfinance.com/ticker/IMMX" />
About Immix Biopharma Inc. (IMMX)

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Industry

Biotechnology

Sector

Healthcare